The Vanguard Group Discloses Stake in Avadel Pharmaceuticals

The Vanguard Group, Inc. has filed a Form 8.3 in compliance with the Irish Takeover Panel Act, 1997, to disclose its interest in Avadel Pharmaceuticals plc. As of October 30, 2025, Vanguard disclosed ownership of 5,519,416 ordinary shares, representing a 5.67% stake in Avadel. Notably, Vanguard Group purchased 904 shares at $18.83 each. Other investments or short positions were not indicated. Additionally, Vanguard reported no agreements, indemnities, or option arrangements concerning the securities in focus. This disclosure remains aligned with the organization's transparency requirements.

No other entities related to the offer were disclosed. Moreover, The Vanguard Group confirmed the absence of a Supplemental Form 8, indicating no further derivative positions or rights to subscribe for new securities.